

# Nanoveu Ltd

## Company Update

### Clear winner in Nestle peer reviewed study.....now to market

Nanoveu Ltd (ASX:NVU) and the Nanoshield have been explicitly named (as the copper based ready to employ coating product tested) in the just released peer reviewed study looking at the effectiveness of antiviral coatings in the American Society for Microbiology (ASM) Journal (<https://journals.asm.org/doi/10.1128/AEM.01098-21>), along with Kastus out of Ireland (ROS coating technology) and Zoono (ASX:ZNO) out of New Zealand (QAC spray). The study describes itself as “novel” and “rigorous”, looking to test commercially available products in real life settings, requirements of which are over & above the likes of ISO 21702 and ASTM method E1153. The settings were 1) immediate viral effect after 0, 30 and 120 minutes (+15 minutes contact/drying) against 24-hours for ASTM, 2) The impacts of repeat cleaning after 1, 7, 30 and 90 wipes with a microfibre cloth and water based detergent or alcohol based sanitiser, and 3) effectiveness in the presence of organic material (touching) over 10 to 50 touches. Only the copper compound-based coating (Nanoshield) successfully met all three criteria, with the ROS coating not meeting any, while the QAC spray was ineffective after one clean/wipe and only displayed immediate effectiveness if sprayed on and not wiped post application. While surface/formite transmission of COVID has shown to be less important than previously thought, it has and will continue to be used as an additional measure to mitigate risk and remains relevant for the transmission of other viruses. The application of Nanoshield and daily cleaning with a microfibre cloth after 50+ touches (a typical medium-touch day for self-serve kiosks) looks to be the benchmark for surface protection of commercially available products. The company now has the marketing material to make sales inroads with its distributor base.

### Business model

NVU has developed a number of treated film applications, with the current focus an antiviral & antimicrobial film called Nanoshield. This product is being sold via exclusive and non-exclusive B2B resellers, and potentially to OEMs and direct to larger customers. Resellers will typically add a mark-up to the wholesale price in order to fund the value-add required in the form of product application and maintenance. Additionally, NVU also sells directly to International Multinational accounts which is more suited to higher volume, cookie cutter products cut to specific dimensions for specific application.

### Now to market the relative effectiveness on surfaces

NVU now has a peer reviewed study into the Nanoshield's antiviral effectiveness relative to other commercially available products/technologies on the market (and achieving significantly higher sales – ZNO for example ~NZ\$28m in FY21). In our view this is the missing ingredient for sales momentum with distributors in place across the USA, ANZ, Singapore, Thailand, Vietnam, Malaysia, UK, Turkey, the Philippines, MEA and India.

### Valuation implies \$25m market cap vs \$8.0m currently

We are at the very early stages of product recognition and distributor sign-up, and as a result, framing the take-up in terms of revenue and resulting profit is difficult. Our sales assumptions currently imply an uplift as the product gains traction, and these are unchanged, but the significance of these study results have seen us reduce the discount rate used in our DCF, and as a result our DCF valuation increases from \$0.124/share to \$0.154/share. We continue to note that our sales estimates are well below minimum order requirements required for distributors and sales targets for performance shares.

#### Historical earnings and RaaS Advisory estimates

Year end	Revenue (A\$m)	EBIT reported (A\$m)	NPAT adjusted (A\$m)	EPS(adj) (c)	P/E (x)	EV/Sales (x)
12/20a	0.4	(1.7)	(1.7)	(0.01)	nm	17.61
12/21e	2.6	(1.1)	(1.1)	(0.01)	nm	3.32
12/22e	5.8	(0.1)	(0.1)	(0.00)	nm	1.47
12/23e	7.6	0.4	0.4	0.00	nm	1.09

Source: Company data, RaaS Advisory, Estimates for FY21e, FY22e and FY23e

### Film manufacturing

29<sup>th</sup> July 2021

#### Share details

ASX Code	NVU
Share price (intraday)	\$0.05
Market Capitalisation	\$8.0M
Shares on issue	162.1M
Net cash 30 June 2021	\$0.8M
Free float	~51.6%

#### Share performance (12 months)



#### Upside Case

- New enterprise & distribution customers
- Secures major vending retail/telco partner
- Commercial progress of EyeFlyx and EyeFly

#### Downside Case

- Distributors fail to penetrate respective markets
- COVID vaccine programs reduce importance of antiviral products
- Ability to secure funding

#### Catalysts

- Follow-up distributor orders on the back of the Nestle study
- Success of Customskins machines on the ground

#### Board of Directors

Alfred Chong	Executive Chairman
Michael van Uffelen	Executive Director/CoSec
Stephen Apedaile	Non-Executive Director
David Nicol	Non-Executive Director

#### Company contact

Alfred Chong (CEO) +61 6557 0155  
info@nanoveu.com

#### RaaS Advisory contacts

John Burgess +61 410 439 723  
john.burgess@raasgroup.com  
Finola Burke +61 414 354 712  
finola.burke@raasgroup.com

## Nestle antiviral trial summary

Nestle Research tested Nanoshield against to other market leading antiviral coating solutions, Zoono Microbe Shield Z-71, a quarternary ammonium compounds (QAC) based surface spray, and Kastus, an antimicrobial surface coating for glass. Initial testing was conducted using the HCoV-299E virus (a recognised surrogate for SARS-CoV-2). The Kastus product showed no antiviral activity at 120 minutes and was not tested further. The immediate antiviral activity of Zoono Microbe Shield Z-71 was only observed when the spray coating was applied without subsequent wiping. Subsequent simulated real-world cleaning procedures of the coated surfaces was done using microfibre cloths and both a water based detergent and 70% ethanol. The coatings were wiped with both solutions 1, 7, 30 and 90 times. The antiviral activity of Nanoshield remained intact after 90 wipes with a microfiber cloth using both water-based detergent and alcohol sanitiser. The antiviral activity of Zoono Microbe Shield Z-71; was completely removed after one round of cleaning with either cleaning product.

In the table below we summarise the key products tested and results (with commentary) from the three “real life” settings tested, immediate viral effects, performance under repeated cleaning and performance after touching. NVU’s Nanoshield is positioned to become the benchmark of antiviral surface protection.

<b>Exhibit 1: A layman’s summary of the peer reviewed Nestle antiviral study</b>				
Variable	Kastus	Zoono	Nanoshield	Comments
Technology	ROS Coating	QAC Spray	Copper coating	
Immediate effect	None	Effective	Effective	
Comments	Some reaction to influenza after 4-hours of UV-A light exposure	Only if the QAC coating was applied by spraying without subsequent wiping	SARS-CoV-2 inactivation >4.0 log (99.99%) against 1.6 log for QAC at time zero (15 minutes contact)	Nestle did not progress with Kastus product post tests on immediate effectiveness
Repeated cleaning	Not investigated further	None	Effective	
		Any physical wiping, with or without cleaning agents appeared to remove coating	Remained intact for at least 90 rounds of cleaning. Maintained using ethanol & detergent	Nanoshield particularly effective under repeat cleaning
Finger touching	Not investigated further	Effective	Effective	
			High protection after 10-touches (log >4.0 log), lower but still effective after 50 touches (1.4 log)	While effectiveness reduces on number of touches, still some effectiveness at 50, and cleaning restores full efficacy
Summary	Was not tested following immediate efficacy test.	Failed repeat cleaning at first clean and only effective if not wiped	Passed all three real life tests, particularly strong in repeat cleaning	Nanoshield positioned to become the benchmark antiviral surface protectant
FY21(f) revenue (A\$)	NA	\$26.5m	\$0.9m	
	Estimates range between US\$1m and US\$5m – recently raised €5.6m	NZ\$27.8m unaudited for FY21	Actuals for 2HCY20 and RaaS estimate for 1HCY21	Huge upside for Nanoshield given Zoono sales
Source: ASM publication, Company financials, RaaS estimates				

## Base Case DCF valuation increased to \$0.154/share (previously \$0.124/share)

We are not changing our sales or earnings estimates at this stage, but given the significance of the Nestle study results we have reduced our discount rate via the beta (from 1.5x to 1.3x) on the belief our estimates now come with lower risk. As a result our valuation using the existing share count increases from \$0.124/share to \$0.154/share. Key risks from here are funding related and resources surrounding the marketing of these results.

### Exhibit 2: Base Case DCF valuation

	Parameters
Discount rate (WACC)	11.1%
Terminal Growth Rate	2.0%
Beta	1.3
Present value of free cashflows (\$m)	3.6
Terminal value (\$m)	20.5
Plus Net Cash at 30 June	0.8
Equity value (\$m)	25.0
Shares on issue (m)	162
<b>Equity value per share</b>	<b>\$0.154</b>

Source: RaaS estimates

### Exhibit 3: Financial Summary

Nanoveu Ltd						Share price (28 July 2021)						A\$		0.050	
Profit and Loss (A\$m)						Interim (A\$m)		H120	H220	H121F	H221F	H122F	H222F		
Y/E 31 December	FY19A	FY20A	FY21F	FY22F	FY23F	Revenue	0.0	0.3	0.6	2.0	3.1	2.7			
Revenue	0.1	0.4	2.6	5.8	7.6	EBITDA	(0.8)	(0.9)	(0.8)	(0.3)	0.1	(0.2)			
Gross profit	(0.0)	0.1	1.0	2.3	3.0	EBIT	(0.8)	(0.9)	(0.8)	(0.3)	0.1	(0.2)			
GP margin %	(24.6%)	34.6%	40.0%	40.0%	40.0%	NPAT (normalised)	(0.8)	(1.0)	(0.8)	(0.4)	0.0	(0.2)			
Underlying EBITDA	(2.8)	(1.7)	(1.1)	(0.1)	0.4	Minorities	0.0	0.0	0.0	0.0	0.0	0.0			
Depn	0.0	0.0	0.0	0.0	0.0	NPAT (reported)	(0.8)	(1.0)	(0.8)	(0.4)	0.0	(0.2)			
Amort	0.0	0.0	0.0	0.0	0.0	EPS (normalised)	nm	(0.007)	(0.005)	(0.002)	0.000	(0.001)			
EBIT	(2.8)	(1.7)	(1.1)	(0.1)	0.4	EPS (reported)	nm	(0.007)	(0.005)	(0.002)	0.000	(0.001)			
Interest income	0.0	0.0	0.0	0.0	0.0	Dividend (cps)	0.000	0.000	0.000	0.000	0.000	0.000			
Tax	0.0	0.0	0.0	0.0	0.0	Imputation									
NPAT	(2.8)	(1.7)	(1.1)	(0.1)	0.4	Operating cash flow	na	na	na	na	na	na			
Adjustments	0.0	0.0	0.0	0.0	0.0	Free Cash flow	na	na	na	na	na	na			
Adjusted NPAT	(2.8)	(1.7)	(1.1)	(0.1)	0.4	Divisionals	H120	H220	H121F	H221F	H122F	H222F			
Abnormals (net)	(0.5)	(0.1)	0.0	0.0	0.0										
NPAT (reported)	(3.2)	(1.8)	(1.1)	(0.1)	0.4										
Cash flow (A\$m)															
Y/E 31 December	FY19A	FY20A	FY21F	FY22F	FY23F	Total Revenue	0.0	0.3	0.6	2.0	3.1	2.7			
EBITDA	(2.8)	(1.7)	(1.1)	(0.1)	0.4										
Interest	0.0	0.0	0.0	0.0	0.0	Gross profit	0.0	0.1	0.2	0.8	1.2	1.1			
Tax	0.0	0.0	0.0	0.0	0.0	Underlying GP Margin %	23.5%	35.1%	40.0%	40.0%	40.0%	40.0%			
Working capital changes	(2.4)	0.7	0.4	(0.0)	0.1	Operating Costs									
Operating cash flow	(5.2)	(1.0)	(0.7)	(0.1)	0.5	Selling & Distribution	0.2	0.3	0.3	0.4	0.3	0.4			
Mtce capex	0.1	0.0	0.0	0.0	0.0	Administration	0.5	0.6	0.6	0.7	0.7	0.7			
Free cash flow	(5.1)	(1.0)	(0.7)	(0.1)	0.5	Other	0.1	0.1	0.1	0.1	0.2	0.1			
Growth capex	0.0	0.0	0.0	0.0	0.0	Total costs	0.8	1.0	1.0	1.1	1.1	1.3			
Acquisitions/Disposals	0.0	0.0	0.0	0.0	0.0										
Other	0.0	0.0	0.0	0.0	0.0	EBITDA	(0.8)	(0.9)	(0.8)	(0.3)	0.1	(0.2)			
Cash flow pre financing	(5.1)	(1.0)	(0.7)	(0.1)	0.5	EBITDA margin %	#####	(260.1%)	(133.9%)	(15.7%)	2.8%	(5.9%)			
Equity issues	0.0	0.0	0.0	0.0	0.0	Margins, Leverage, Returns		FY19A	FY20A	FY21F	FY22F	FY23F			
Debt	0.0	1.3	1.2	0.6	0.0	EBITDA margin %		(4573.8%)	(471.3%)	(42.1%)	-1.3%	4.6%			
Net Dividends paid	0.0	0.0	0.0	0.0	0.0	EBIT margin %		(4573.8%)	(471.3%)	(42.1%)	-1.3%	4.6%			
Net cash flow for year	(5.1)	0.3	0.5	0.5	0.5	NPAT margin (pre significant items)		(4516.4%)	(459.1%)	(42.1%)	-1.3%	4.6%			
Balance sheet (A\$m)															
Y/E 31 December	FY19A	FY20A	FY21F	FY22F	FY23F	Net Debt (Cash)		-2.2	-0.8	-0.4	-1.0	-1.2			
Cash	2.2	1.1	0.8	1.3	1.5	Net debt/EBITDA (x)	(x)	0.8 x	0.5 x	0.4 x	13.1 x	-3.4 x			
Accounts receivable	0.2	0.2	0.5	0.6	0.8	ND/ND+Equity (%)	(%)	53.1%	40.6%	25.2%	34.3%	35.1%			
Inventory	0.0	0.4	0.4	0.4	0.4	EBIT interest cover (x)	(x)	n/a	n/a	n/a	n/a	0.0x			
Other current assets	0.0	0.0	0.1	0.1	0.1	ROA		nm	(79.6%)	(59.0%)	(3.4%)	12.8%			
Total current assets	2.4	1.7	1.8	2.4	2.9	ROE		nm	nm	nm	nm	nm			
PPE	0.1	0.1	0.1	0.1	0.1	ROIC		nm	nm	nm	nm	nm			
Goodwill	0.0	0.0	0.0	0.0	0.0	NTA (per share)									
Right of use asset	0.0	0.0	0.0	0.0	0.0	Working capital		-0.3	0.3	0.7	0.7	0.8			
Deferred tax asset	0.0	0.0	0.0	0.0	0.0	WC/Sales (%)		(557.4%)	83.7%	26.5%	11.5%	10.1%			
Other	0.0	0.0	0.0	0.0	0.0	Revenue growth		nm	501.4%	602.0%	125.3%	31.4%			
Total non current assets	0.1	0.1	0.1	0.1	0.1	EBIT growth pa		nm	nm	n/a	n/a	(575.3%)			
Total Assets	2.6	1.8	1.9	2.5	3.0	Pricing		FY19A	FY20A	FY21F	FY22F	FY23F			
Accounts payable	0.5	0.2	0.2	0.3	0.4	No of shares (y/e)	(m)	132.5	135.0	166.7	176.0	176.0			
Short term debt	0.0	0.3	0.3	0.3	0.3	Weighted Av Dil Shares	(m)	132.5	135.0	166.7	176.0	176.0			
Provisions	0.0	0.0	0.0	0.0	0.0										
Lease liabilities/other	0.0	0.0	0.0	0.0	0.0	EPS Reported	cps	nm	(0.013)	(0.006)	(0.000)	0.002			
Total current liabilities	0.6	0.6	0.5	0.7	0.8	EPS Normalised/Diluted	cps	nm	(0.012)	(0.006)	(0.000)	0.002			
Long term debt	0.0	0.0	0.0	0.0	0.0	EPS growth (norm/dil)		nm	nm	-48%	n/a	-575%			
Other non current liab	0.0	0.0	0.0	0.0	0.0	DPS	cps								
Total long term liabilities	0.0	0.0	0.0	0.0	0.0	DPS Growth		n/a	n/a	n/a	n/a	n/a			
Total Liabilities	0.6	0.6	0.5	0.7	0.8	Dividend yield		0.0%	0.0%	0.0%	0.0%	0.0%			
Net Assets	2.0	1.2	1.3	1.9	2.2	Dividend imputation		30	30	30	30	30			
						PE (x)			nm	-	7.7	-			
						PE market		18	18	18	18	18			
Share capital	13.3	14.2	15.4	16.0	16.0	Premium/(discount)			nm	(142.8%)	(759.1%)	38.7%			
Retained Earnings	(10.2)	(11.9)	(13.0)	(13.1)	(12.8)	EV/EBITDA		(1.6)	(3.4)	(7.3)	(105.6)	21.6			
Reserves	(1.2)	(1.1)	(1.1)	(1.1)	(1.1)	FCF/Share	cps	-0.2	-1.7	-0.9	0.0	0.1			
Minorities	0.0	0.0	0.0	0.0	0.0	Price/FCF share		-25.4	-3.0	-5.6	-109.7	39.0			
Total Shareholder funds	1.9	1.2	1.3	1.9	2.2	Free Cash flow Yield		(3.3%)	(28.9%)	(18.8%)	(1.0%)	2.9%			

# FINANCIAL SERVICES GUIDE

**RaaS Advisory Pty Ltd**

**ABN 99 614 783 363**

**Corporate Authorised Representative, number 1248415**

**of**

**BR SECURITIES AUSTRALIA PTY LTD**

**ABN 92 168 734 530**

**AFSL 456663**

**Effective Date: 6<sup>th</sup> May 2021**

### About Us

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License ("AFSL") number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR.

This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS's services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Suite 5GB, Level 5, 33 Queen Street, Brisbane, QLD, 4000

RaaS, 20 Halls Road Arcadia, NSW 2159

P: +61 414 354712

E: [finola.burke@raasgroup.com](mailto:finola.burke@raasgroup.com)

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

**What Financial Services are we authorised to provide?** RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
  - Securities
- deal on behalf of retail and wholesale clients in relation to
  - Securities

The distribution of this FSG by RaaS is authorized by BR.

### Our general advice service

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

### Our dealing service

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application form if needed.

### How are we paid?

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

### Associations and Relationships

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS's representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

### Complaints

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR's internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren't satisfied with an outcome, you may contact AFCA, see below. BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: [www.afca.org.au](http://www.afca.org.au); Email: [info@afca.org.au](mailto:info@afca.org.au); Telephone: 1800931678 (free call)

In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

### Professional Indemnity Insurance

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.

#### DISCLAIMERS and DISCLOSURES

This report has been commissioned by Nanoveu Ltd prepared and issued by RaaS Advisory Pty Ltd. RaaS Advisory has been paid a fee to prepare this report. RaaS Advisory's principals, employees and associates may hold shares in companies that are covered and, if so, this will be clearly stated on the front page of each report. This research is issued in Australia by RaaS Advisory and any access to it should be read in conjunction with the Financial Services Guide on the preceding two pages. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. RaaS Advisory provides this financial advice as an honest and reasonable opinion held at a point in time about an investment's risk profile and merit and the information is provided by the RaaS Advisory in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. RaaS Advisory has no obligation to update the opinion unless RaaS Advisory is currently contracted to provide such an updated opinion. RaaS Advisory does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise.

The science of climate change is common knowledge and its impacts may damage the global economy. Mitigating climate change may also disrupt the global economy. Investors need to make their own assessments and we disclaim any liability for the impact of either climate change or mitigating strategies on any investment we recommend.

Investors are responsible for their own investment decisions, unless a contract stipulates otherwise. RaaS Advisory does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, RaaS Advisory shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, RaaS Advisory limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable. Copyright 2021 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.